India’s COVID vaccine shown 78% effective in phase 3 trial

Nov 11, 2021

Two doses offer 77.8% efficacy against symptomatic COVID-19 but about 65% against the Delta variant.

Mary Van Beusekom | News Writer | CIDRAP NewsNov 11, 2021Two doses offer 77.8% efficacy against symptomatic COVID-19 but about 65% against the Delta variant.Read More

Leave a Reply

Your email address will not be published.